Synthesis of Natural O-Linked Carba-Disaccharides, (+)- and (-)-Pericosine E, and Their Analogues as α-Glucosidase Inhibitors.

Pericosine E (6), a metabolite of Periconia byssoides OUPS-N133 was originally isolated from the sea hare Aplysia kurodai, which exists as an enantiomeric mixture in nature. The enantiospecific syntheses of both enantiomers of Periconia byssoides OUPS-N133 has been achieved, along with six stereoisomers, using a common simple synthetic strategy. For these efficient syntheses, highly regio- and steroselective processes for the preparation of bromohydrin and anti-epoxide intermediates were applied. In order to access the unique O-linked carbadisaccharide structure, coupling of chlorohydrin as a donor and anti-epoxide as an acceptor was achieved using catalytic BF₃·Et₂O. Most of the synthesized compounds exhibited selectively significant inhibitory activity against α-glycosidase derived from yeast. The strongest analog showed almost 50 times the activity of the positive control, deoxynojirimycin.

1. Introduction

As the first WHO Global report says “422 million adults were living with diabetes in 2014” and “diabetes caused 1.5 million death in 2012”, conquering diabetes or obesity is one of the most serious problems facing the humankind [1]. Discovering new potent α-glucosidase inhibitors is one way that pharmacists can contribute to resolving this problem. Successful and well-known examples include the clinically used anti-diabetes drugs acarbose, voglibose, and miglitol. Acarbose and voglibose molecules contain carbasugar moieties, whereas miglitol has an azasugar structure. Most candidates for glycosidase inhibitors are nitrogen-containing molecules, such as azasugars, bicyclic molecules with a nitrogen atom at the juncture, and N-linked pseudo-oligosaccharides [2]. Recent studies on thiosugar-containing α-glucosidase inhibitors have also made progress [3]. However, there have been only a few reports on pseudo-oligosaccharides constructed of only carbasugars [4,5,6,7,8]. Shing and Hudlicky independently synthesized such molecules, providing a new class of unique glycosidase inhibitors [4,5,6,7]. As this background shows, the synthetic study of carba-oligosaccharides as potential glycosidase inhibitors is a challenging step into a new research area for diabetes drugs discovery.

In the course of our continuing studies on the synthesis of bioactive marine natural products, we have studied and reported on the total syntheses of pericosines [9,10,11,12,13,14,15]. Pericosines A–E (1–6) are unique carbasugar-type metabolites of the fungus Periconia byssoides OUPS-N133, which was originally isolated from the sea hare Aplysia kurodai [16,17,18]. As pericosine A (1) showed remarkable anticancer activity, several other research groups have also undertaken and reported the syntheses of pericosines [19,20,21,22,23,24,25]. As such, our synthetic strategy towards pericosines has changed to a biomimetic method, in which two kinds of epoxides act as common intermediates [12,13,14,15]. Recently, the Cichewicz group reported the isolation of maximiscin, which shows potent inhibition against melanoma cell line UACC-62 and contains a pericosine moiety, as a fungal metabolite of Tolypocladium sp. [26,27]. However, our attention was focused on the co-isolation of (+)-pericosine A (1) and precursor pericoside (7) from the fungal extract (our second synthetic intermediate, syn-epoxide 11, extracted later) [27]. These natural products can reduce the antifungal activities of antibiotics. Another noteworthy synthesis is that of a pericosine analogue, along with cyathiformine B, streptol, and MK7607, using the regio- and stereo-controlled ring opening of allylic oxides reported by Lewis and co-workers [28]. These studies implied that the syntheses of pericosines will become increasingly important in the future.

Among the pericosine family, pericosine E (6) is extremely unique, containing an O-linked carbadisaccharide structure between the pericosine-A-like moiety and pericosine-B-like moiety with the opposite absolute configurations (Figure 1). Indeed, (−)-pericosine E (6) has the structure of (−)-pericosine A and that of (+)-pericosine B linked together. To our knowledge, pericosine E (6) is the only example of a natural O-linked carbadisaccharide to date [29]. Furthermore, natural pericosine E (6) was reported to exist as an enantiomeric mixture [17]. As the stereochemistry is highly complicated, the synthesis of 6 and its analogs presents an exciting challenge toward molecules with biological activity, such as glycosidase inhibitory activities. A part of this work, the first total synthesis of (−)-6, was recently published in preliminary form [14]. The synthetic strategy and newly developed technologies in the previous paper could be applied to the as yet unsynthesized natural minor enantiomer (+)-pericosine E, along with its analogs. Herein, we describe the enantiospecific syntheses of both enantiomers and six diastereomers of 6, and their glycosidase inhibitory activities.

Figure 1

Structures of pericosines (1–6) and related natural products.

2. Results and Discussion

2.1. Retrosynthetic Strategy

Based on our previous synthetic route for pericosines A–C, we envisioned the retrosynthesis of (−)-6 as summarized in Scheme 1 [13,14]. In this strategy, we illustrated the absolute configuration of 6 as being made up of (−)-pericosine A (1) and (+)-pericosine B (2). This structural pattern is denoted as (−pA, +pB)-type hereafter for better understanding of the puzzling stereochemistry in pericosine E and its analogs. The former corresponds with donor chlorohydrin 9, while the latter corresponds with acceptor anti-epoxide 10, in the key condensation reaction. As mentioned above, donor 9 could be derived from syn-epoxide 11, which corresponds with a pericoxide proven to be the precursor of pericosine A in the culture of Tolypocladium sp. [27]. Therefore, our strategy might be biomimetic. Since both enantiomers of common intermediates of unstable diene (13) are available from commercially available (−)-quinic acid or (−)-shikimic acid [14,15,30], the synthesis of (+)-6, (+pA, −pB)-type, was also possible using essentially the same approach. Furthermore, coupling chlorohydrin (−)-9 with anti-epoxide (−)-10 will lead a new analog, (−pA, −pB)-type, which might correspond to undiscovered natural products.

Scheme 1

Retrosynthetic strategy of (−)-pericosine E (6).

2.2. Preparation of Both Enantiomers of Cholohydrin and Anti-Epoxide

In order to achieve these total syntheses effectively, two innovations were required: the regio- and steroselective bromohydrination of unstable diene 13 to bromohydrin 12, and the epoxidation of 13 to give 10. The former reaction was carried out with N-bromosuccinimide (NBS) in an acetonitrile–H2O (3:2) solvent system using a 5 mg/mL substrate concentration, while the latter was realized by the addition of 13 to methyl (1,1,1-trifluoromethyl)dioxirane, TFDO) [31,32], prepared in situ at −15 °C in H2O–1,1,1-trifluoroacetone (1:1), affording 10 exclusively. When TFDO was generated and reacted with 13 at 0 °C, the product ratio of 10 and its regioisomer, which was inseparable from 10, was ca. 15:1. Gradual and careful addition of Oxone® at −15 °C to a H2O–trifluoroacetone solvent system for in situ generation of TFDO was required in this process, otherwise the inseparable regioisomer was present in the product [12,28,33]. Details of reaction condition optimization can be found in our previous communication [15].

Using these new methods, both enantiomers of chlorohydrin 9 and anti-epoxide 10 were prepared, as shown in Scheme 2. Scheme 2a summarized syntheses of (−)-9 and (+)-10 from (−)-shikimic acid via diene (+)-13. A methanol solution of (−)-shikimic acid and cyclohexanone, with a catalytic amount of camphorsulfonic acid (CSA), was heated under microwave irradiation (MW; 160 °C, 30 min) to give alcohol 14 in 92% yield. Then, a CH2Cl2 solution of obtained alcohol 14, triflic anhydride (1.2 equivalent (eq.)), pyridine, and dimethylaminopyridine (2.4 eq.) was again heated under MW irradiation (120 °C, 30 min) to give (+)-13 in 59% yield [34]. After one-pot dehydration, bromohydrination of (+)-13 was carried out as described above, to afford (+)-12 in 55% yield, which was then treated with lithium hexamethyldisilazide (LHMDS) at −78 °C, causing an intramolecular SN2 reaction to afford epoxide (−)-11 in an 83% yield. Treatment of epoxide (−)-11 with HCl in dry diethyl ether yielded chlorohydrin (−)-9 at an 83% yield. Meanwhile, epoxidation of (+)-13 with TFDO gave (−)-10 at a 72% yield.

Scheme 2

Preparation of both enantiomers of chlorohydrin (9) and anti-epoxide (10). (a) Synthesis of (−)-9 and (−)-10 from (−)-shikimic acid; (b) synthesis of (+)-9 and (+)-10 from (−)-quinic acid. LHMDS: lithium hexamethyldisilazide; MW: microwave; NBS: N-bromosuccinimide.

The preparation of (+)-9 and (+)-10 from (−)-quinic acid is illustrated in Scheme 2b. Initially, (−)-quinic acid was converted to alcohol 15 using a known method. MW-aided dehydration of 15, similar to that described above, afforded a lower yield of the desired (−)-13, requiring purification to remove undesired byproducts. A plausible explanation for depressed yield of (−)-13 in the MW-aided reaction is that instability of the triflate derived from 15 in the reaction temperature might cause some degradation into undesired byproducts. The 4β-oxygen atom in the triflate was deduced to be more positively charged by a neighboring effect of the 5β-OTf group than that in 15. Then, transformation of 15 into diene (−)-13 was carried out using a known two-step sequence, 5β-O-triflylation of 15 followed by elimination of the leaving group with cesium acetate in N,N-dimethylformamide (DMF), to afford an 88% yield [35]. Diene (−)-13 was converted to (−)-12 and (+)-10 using the same methods described above. Transformation of (−)-12 into (+)-9 via (+)-11 was carried out using a literature method [14].

2.3. Synthesis of Both Enantiomers of Pericosine E and Analogs

With the four required intermediates, (+)/(−)-9 and (+)/(−)-10, in hand, the synthesis of (−)-pericosine E (6) was carried out from (−)-9 and (+)-10, as shown in Scheme 3. The ether linkage between (−)-9 and (+)-10 was formed by treatment with BF3·Et2O (0.1 eq.) in CH2Cl2 at room temperature, affording condensation product (−)-8 at 52% isolated yield [8]. Alcohol (−)-8 was treated with Dess–Martin periodinane (DMP) to give a crude inseparable mixture of desired ketone 19 and an unidentified compound. Without separation, the crude mixture containing 19 was reduced with NaBH4 to afford epimerized alcohol (−)-20 in 34% yield over two steps. The stereochemistry of (−)-8 and (−)-20 was confirmed based on their detailed two-dimensional (2D) NMR analyses. In the NOESY spectrum of (−)-8, H-6′ correlated with H-4′ and 5′-OH, supporting the configurations of H-5′ and H-6′. For (−)-20, the NOESY cross peak H-3′/H-5′ suggested the configuration of H-5′. Finally, treatment of (−)-20 with trifluoroacetic acid in methanol gave the desired product, (−)-6, whose spectral data, except specific rotation, showed satisfactory agreement with the natural product. The specific rotation of synthetic 6 was [α]D −68.3, whereas that reported for natural 6 was only −31.5 [17]. Thus, we achieved the first total synthesis of (−)-pericosine E (6) and assigned the absolute configuration of the naturally dominant enantiomer of 6 to (3R,4R,5R,6R)-methyl 6-chloro-3,4-dihydroxy-5-{[(1R,4S,5S,6S)-4,5,6-trihydroxy-2-(methoxycarbonyl)cyclohex-2-en-1-yl]oxy}cyclohex-1-enecarboxylate. The results suggested a (−)-6/(+)-6 ratio of roughly 3:1 in the natural product.

Scheme 3

Synthesis of pericosine E (6) and analogs. (a) Synthesis (−)-6, (−)-21, (+)-23, and (+)-22 from (+)-10 and (−)-9 or (+)-9; (b) synthesis of (+)-6, (+)-21, (−)-23, and (−)-22 from (−)-10 and (+)-9 or (−)-9. DMP: Dess-Martin periodinane; TFA: trifluoroacetic acid.

The similar deprotection of (−)-8 progressed slowly, taking three days, and afforded the 5-epimer of (−)-pericosine E, (−)-21, at a 55% yield. The same deprotection aided by MW irradiation (100 °C, 5 min) resulted in a lower yield (34%) of (−)-21.

We continued the synthesis of the naturally occurring minor enantiomer (+)-6 and its analogs using the same strategy. (+)-Pericosine E (6) and its C5-epimer, (+)-21, were synthesized from (+)-9 and (−)-10 (Scheme 3b).

Analog (+)-22, which corresponds to the (+pA, −pB)-type, and its epimer (+)-23 were also synthesized from (+)-9 and (+)-10 (Scheme 3a). Ether formation between (+)-9 and (+)-10 to give (+)-24, followed by Dess–Martin oxidation and NaBH4 reduction, proceeded to afford (+)-25 in a similar fashion to the synthesis of 6. However, the final deprotection of (+)-24 or (+)-25 at room temperature did not occur, even after a prolonged reaction time. Thus, MW-aided deprotection was applied to this step (100 °C, 40 min) to afford the desired carba-disaccharides (+)-23 and (+)-22 in 47% and 62% yields, respectively. The configurations of 24 and 25 were confirmed by NOESY analyses. Cross peaks H-6′/H-4′ and 5′-OH were observed in the NOESY spectrum of 24, as seen for 8. The NOESY spectrum of 25 showed H-3′/H-5′ correlation, as seen for 20. The enantiomer (−)-22, (−pA, −pB)-type, and its epimer (−)-23 were prepared from (−)-9 and (−)-10 in the same manner (Scheme 3b).

In order to extend this scheme to a variety of stereoisomeric analogs, such as (+pA, +pC), (+pA, −pC), (−pA, +pC), and (−pA, −pC)-type of compounds, we attempted the challenging coupling of syn,syn-epoxide (−)-11 with alcohols 15 and (+)/(−)-9 under various conditions. Unfortunately, none of the trials gave the desired O-linked carba-disaccharides derived from 11, despite the epoxide being consumed. These failures were contrary to our expectations for 11 as an acceptor molecule, as it seemed that 11 would react with alcohols more easily than 10 due to the steric demand of 11. The reason for condensations not occurring with 11 is still not known.

2.4. Evaluation of Inhibitory Activities against Glycosidases

Eight samples synthesized here were used in a biological assay against three glycosidases, namely α-glucosidase (yeast), β-glucosidase (sweet almond), and α-mannosidase (Jack bean) [36]. The results are shown in Table 1. Six carba-disaccharides of eight samples showed significant α-glucosidase inhibition, but no inhibition was observed against β-glucosidase or α-mannosidase. Naturally preferred enantiomer (−)-6 and its epimer (−)-21 showed α-glucosidase inhibitory activity, with almost one-third the potency of deoxynojirimycin (DNJ), used as a positive control. The IC50 values were 1.5 × 10−3 M for (−)-6 and 1.8 × 10−3 M for (−)-21. To our surprise, the naturally occurring minor enantiomer, (+)-6, gave better inhibition (IC50: 3.1 × 10−5 M) than the major enantiomer, (−)-6. Among all the compounds synthesized in this study, (−)-22, (−pA, −pB)-type exhibited the strongest activity, being almost 50-fold more potent than DNJ, whereas enantiomer (−)-23 showed no activity. From these results, compounds made from (−)-10 as an acceptor are generally excellent inhibitors.

Table 1

Evaluation of anti-glycosidase activity of the synthesized compounds.

Compound	IC50 (M)
	α-Glucosidase a	β-Glucosidase b	α-Mannosidase c
(−)-pericosine E (6)	1.5 × 10−3	NI d	NI
(−)-21	1.8 × 10−3	NI	NI
(+)-pericosine E (6)	3.1 × 10−5	NI	NI
(+)-21	3.2 × 10−3	NI	NI
(+)-22	NI	NI	NI
(+)-23	5.1 × 10−3	NI	NI
(−)-22	1.2 × 10−5	NI	NI
(−)-23	NI	NI	NI
Deoxynojirimycin (DNJ)	6.3 × 10−4	5.5 × 10−4	NI
Deoxymannojirimycin	NI	NI	6.4 × 10−4

a Yeast; b Sweet almond; c Jack bean; d No inhibition.

3. Conclusions

We have achieved the first total synthesis of both enantiomers of pericosine E (6), which are metabolites of Periconia byssoides OUPS-N133 isolated from the sea hare Aplysia kurodai. The total synthesis elucidated the absolute configuration of the naturally preferred enantiomer to be (−)-6. Using this simple and efficient strategy, pericosine E and seven further stereoisomers were prepared. Almost all the synthesized chlorine-containing O-linked carbadisaccharides showed significant inhibitory activity against only α-glycosidase derived from yeast. In general, compounds containing a (−)-pericosine B-like portion as an acceptor showed better activity. The most potent compound, (−)-22, exhibited ca. 50 times the α-glycosidase inhibitory activity of DNJ, a positive control. These results suggest that O-linked carba-oligosaccharides based on pericosine E are promising seeds for a new class of diabetes drugs. Further study of the syntheses of O-linked carbadisaccharides without chlorine is ongoing. The anti-glycosidase assay will elucidate the role of the chlorine atom.

4. Experimental Section

Infrared (IR) spectra were obtained using a PerkinElmer FT-IR spectrometer 1720X (Perkin Elmer, Waltham, MA, USA). High Resolution Mass Spectra (HRMS) were obtained using a JEOL JMS-700 (2) mass spectrometer (JEOL, Tokyo, Japan). NMR spectra were recorded at 27 °C on Agilent 300-, 400-MR-DD2 (Agilent Technologies, Santa Clara, CA, USA), Agilent 600-DD2 (Agilent Technologies, Santa Clara, CA, USA), Varian Marcury-300BB (Varian, Palo Alto, CA, USA), and Varian Unity-500 spectrometers in CDCl3 using tetramethylsilane (TMS) as the internal standard. Liquid column chromatography was conducted on silica gel (Nacalai, silica gel 60, mesh 70–230 or 230–400). Analytical thin layer chromatography (TLC) was performed on pre-coated Merck glass plates (silica gel 60 F254) and compounds were detected by dipping the plates in an ethanol solution of phosphomolybdic acid, followed by heating. Microwave-aided reactions were carried out using a Biotage Initiator® reactor (PartnerTech Atvidaberg AB for Biotage Sweden AB, Uppsala, Sweden). Flash chromatography was carried out using Biotage Isolera One® purification system (PartnerTech Atvidaberg AB for Biotage Sweden AB, Uppsala, Sweden). Dry CH2Cl2, dry tetrahydrofuran (THF), NaBH4, trifluoroacetic acid (TFA), pyridine, and NBS were purchased from Wako Pure Chemical Industries (Wako Pure Chemical Industries, Tokyo, Japan). meta-Chloroperbenzoic Acid (mCPBA) and hexamethyldisilazane (HMDS) were purchased from nacalai tesque, Inc. (nacalai tesque, Inc., Kyoto, Japan). Cyclohexanone, camphorsulfonic acid (CSA), HCl in Et2O, trifluoroacetone, BF3·Et2O, and n-BuLi were purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). Tf2O, CsOAc, and Dess-Martin periodinane (DMP) were purchased from TCI (Tokyo Chemical Industry Co. Ltd., Tokyo, Japan). (−)-Shikimic acid was purchased from Carbosynth, Ltd. (UK). (−)-Quinic acid was purchased from Merck (Merck & Co., Inc., Darmstadt, Germany). α-Glucosidase (Yeast, lot. 26010), β-glucosidase (Sweet Almond, lot. 81241), α-mannosidase (Jack Bean, lot. 055K7047), and deoxymannojirimycin were purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). 1-Deoxynojirimycin was isolated from leaves of the plant Morus alba L.

4.1. Bromohydrination of (+)-

NBS (48 mg, 1.2 mmol) at 0 °C was added with stirring to a solution of diene (+)-13 (58 mg, 0.23 mmol) in acetonitrile-H2O (1:1.5, 12 mL). After stirring for 3 h at room temperature (RT), the reaction mixture was treated with aqueous (aq.) Na2S2O3 (10 mL) and saturated (sat.) aq. NaHCO3 (10 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO4 and filtered, and the solvent was removed under reduced pressure to afford a crude residue. Purification by silica gel column chromatography (CH2Cl2) afforded (+)-12 (44 mg, 55%).

(+)-12: Colorless oil; [α] +23.1 (c 0.06, CHCl3); IR (liquid film) νmax 3524 (OH), 1715 (C=O), 1660 (C=C) cm−1; 1H-NMR (CDCl3, 400 MHz, ppm) δ 1.25–1.70 (10H, m), 3.46 (1H, d, J = 10.7 Hz, 6-OH), 3.84 (3H, s, COOMe), 4.59 (1H, dd, J = 4.0, 2.8 Hz, H-5), 4.67 (1H, dddd, J = 4.9, 4.1, 1.9, 1.1 Hz, H-4), 4.74 (1H, br dd, J = 10.7, 2.7 Hz, H-6), 4.84 (1H, dd, J = 4.5, 3.3 Hz, H-3), 6.88 (1H, dd, J = 3.3, 1.0 Hz, H-2); 13C-NMR (CDCl3, 100 MHz, ppm) δ 23.6, 23.8, 24.7, 35.8, 37.7, 45.1, 52.4, 66.8, 71.3, 75.4, 112.8, 129.8, 135.6, 165.9; HRMS m/z calcd. for C14H19O579Br (M)+, 346.0416; found, 346.0415, m/z calcd. for C14H19O581Br (M)+, 348.0396; found, 348.0391.

4.2. Methyl (3R,4R,5S,6S)-3,4-O-cyclohexilidene-3,4-dihydroxy-5,6-epoxy-1-cyclohex-ene-1-carboxy-late (−)-

To a solution of 1,1,1,3,3,3-hexamethyldisilazane (0.19 mL, 0.81 mmol) in dry THF (3 mL), 1.6 M n-BuLi in hexane (0.56 mL, 0.81 mmol) was added at −78 °C to give LHMDS. After 30 min the prepared LHMDS solution was added dropwise to a solution of (+)-12 (0.28 g, 0.81 mmol) in THF (5 mL) at −78 °C through a steel cannula under argon atmosphere. After stirring the reaction mixture for 1 h at −78 °C, followed by warming to RT over 1 h, the reaction mixture was treated with sat. aq. NH4Cl (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were dried over MgSO4 and filtered, and the solvent was removed under reduced pressure to afford a crude residue. Purification by silica gel column chromatography (Hexane–EtOAc, 3:1) afforded (−)-11 (0.18 g, 83%) as crystals. (−)-11: White crystals (CH2Cl2); mp 81–84 °C; [α] −5.4 (c 0.98, CHCl3); IR (KBr) νmax 1731 (C=O), 1650 (C=C) cm−1; 1H-NMR (CDCl3, 400 MHz, ppm) δ 1.35–1.80 (10H, m), 3.74 (1H, ddd, J = 4.1, 2.8, 2.0 Hz, H-5), 3.83 (3H, s, COOMe), 4.03 (1H, dd, J = 4.1, 2.1 Hz, H-6), 4.48 (1H, dd, J = 6.6, 2.8 Hz, H-4), 4.73 (1H, ddd, J = 6.6, 5.5, 2.0 Hz, H-3), 7.14 (1H, dd, J = 5.5, 2.0 Hz, H-2); 13C-NMR (CDCl3, 100 MHz, ppm) δ 23.9, 24.1, 25.1, 34.5, 36.8, 49.0, 52.4, 56.2, 69.7, 72.1, 109.4, 132.5, 137.5, 165.4; HRMS m/z calcd. for C14H18O5 (M)+, 266.1155; found. 266.1150.

4.3. Methyl (3R,4R,5R,6R)-6-chloro-3,4-O-cyclohexylidene-3,4,5-trihydroxy-1-cyclo hexene-1-carbo-xylate (−)-

To a solution of (−)-11 (55.9 mg, 0.21 mmol) in dry Et2O (1 mL), 1 M HCl in Et2O (0.31 mL, 0.31 mmol) was added at 0 °C. After stirring for 1 h, the solvent was removed under vacuum to afford a crude residue that was purified by preparative TLC (Hexane–EtOAc, 4:1) to afford (−)-9 (57.5 mg, 90%) as colorless crystals. (−)-9: Colorless crystals (CHCl3) mp 125–128 °C; [α] −165.0 (c 0.3, CHCl3); IR (KBr) νmax 3360 (OH), 1725 (C=O), 1649 (C=C) cm−1; 1H-NMR (CDCl3, 400 MHz, ppm) δ 1.20–1.80 (10H, m), 2.66 (1H, d, J = 2.4 Hz, 5-OH), 3.83 (3H, s, COOMe), 4.30 (1H, ddd, J = 3.9, 3.8, 2.3 Hz, H-5), 4.70 (1H, ddd, J = 7.5, 3.9, 0.4 Hz, H-4), 4.77 (1H, dd, J = 7.5, 3.0 Hz, H-3), 5.04 (1H, d, J = 3.9 Hz, H-6), 7.18 (1H, d, J = 3.2 Hz, H-2); 13C-NMR (CDCl3, 100 MHz, ppm) δ 23.5, 23.9, 25.0, 33.4, 36.1, 50.9, 52.4, 67.2, 69.6, 71.4, 110.8, 130.2, 137.8, 164.9; HRMS m/z calcd. for C14H19O535Cl (M)+ 302.0921, found 302.0925, m/z calcd. for C14H19O537Cl (M)+, 304.0891; found, 304.0903.

4.4. Synthesis of Anti-Epoxide (−)-

To a solution of (+)-13 (60.0 mg, 0.24 mmol) and NaHCO3 (0.20 g, 2.4 mmol) in trifluoroacetone-H2O (1:1, 2 mL) at −15 °C, Oxone® was added every 15 min (four portions, each portion 0.073 g, 0.12 mmol) with stirring. After 3 h, tert-butyl methyl ether (TBME) (10 mL) was added and the reaction mixture was filtered through Celite. The filtrate was treated with sat. aq. NaHCO3 (10 mL) and extracted with TBME (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent was removed under reduced pressure to afford a crude residue, which was purified by column chromatography (Hexane–EtOAc, 5:1) to afford (−)-10 (46.0 mg, 72%) as a colorless oil. (−)-10: Colorless oil; [α] −20.4 (c 0.29, CHCl3); IR (liquid film) νmax 1730 (C=O), 1647 (C=C) cm−1; 1H-NMR (CDCl3, 500 MHz, ppm) δ 1.35–1.70 (10H, m), 3.69 (1H, br dd, J = 3.7, 2.1 Hz, H-5), 3.84 (3H, s, COOMe), 3.99 (1H, ddd, J = 3.7, 1.6, 0.7 Hz, H-6), 4.58 (1H, dd, J = 6.9, 2.3 Hz, H-3), 4.80 (1H, br d, J = 6.9 Hz, H-4), 6.83 (1H, m, H-2); 13C-NMR (CDCl3, 125 MHz, ppm) δ 23.7, 23.9, 24.9, 35.3, 37.5, 46.1, 49.3, 52.3, 70.0, 70.8, 111.7, 127.2, 140.3, 165.5; HRMS m/z calcd. for C14H18O5 (M)+, 266.1156; found, 266.1158.

4.5. Bromohydrination of (−)-

Diene (−)-13 (1.5 g, 5.9 mmol) was converted to (−)-12 (1.2 g, 57% yield) using the same procedure as for (+)-12.

4.6. Synthesis of (+)-

Bromohydrin (−)-12 (556 mg, 4.3 mmol) was converted to (+)-11 (319 mg, 75% yield) using the same procedure described above.

4.7. Synthesis of (+)-

Epoxide (+)-11 (386 mg, 1.4 mmol) was converted to chlorohydrin (+)-9 (395 mg, 90% yield) using the same procedure described above.

4.8. Synthesis of Anti-Epoxide (+)-

Diene (−)-13 (1.5 g, 5.9 mmol) was oxidized to (+)-10 (1.2 g, 75% yield) using a procedure similar to that for (−)-10. (+)-10: Colorless oil; [α] +24.7 (c 0.68, CHCl3); IR (liquid film) νmax 1722 (C=O), 1654 (C=C) cm−1; 1H-NMR (CDCl3, 600 MHz, ppm) δ 1.34–1.70 (10H, m), 3.68 (1H, dd, J = 3.6, 2.4 Hz, H-5), 3.84 (3H, s, COOMe), 3.99 (1H, ddd, J = 3.8, 1.7, 0.6 Hz, H-6), 4.57 (1H, dd, J = 6.8, 2.4 Hz, H-3), 4.80 (1H, br d, J = 6.8 Hz, H-4), 6.83 (1H, m, H-2); 13C-NMR (CDCl3, 150 MHz, ppm) δ 23.7, 23.9, 24.8, 35.2, 37.4, 46.1, 49.3, 52.3, 70.0, 70.8, 111.6, 127.1, 140.3, 165.5; HRMS m/z calcd. for C14H18O5 (M)+, 266.1156; found, 266.1161.

4.9. Synthesis of (−)- from (−)- and (+)-

To a solution of chlorohydrin (–)-9 (73.0 mg, 0.24 mmol) and epoxide (+)-10 (53.5 mg, 0.20 mmol) in CH2Cl2 (0.6 mL), BF3·Et2O (5 μL, 0.019 mmol) was added at 0 °C. After stirring for 10 min at RT, the reaction mixture was treated with Et3N (5 μL, 0.035 mmol) and concentrated under vacuum to afford a crude residue, which was purified by silica gel column chromatography (Hexane–EtOAc, 3:1) to afford (–)-8 (58.9 mg, 52%) as a white amorphous solid. (−)-8: White amorphous solid; [α] −68.3 (c 0.21, CHCl3); IR (liquid film) νmax 3431 (OH), 1729 (C=O), 1657 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.30–1.80 (20H, m), 3.68 (3H, s, COOMe-8′), 3.81 (3H, s, COOMe-8), 4.01 (1H, ddd, J = 7.3, 6.1, 3.6 Hz, H-5′), 4.21 (1H, dd, J = 7.3, 6.2 Hz, H-4′), 4.37 (1H, ddd, J = 6.2, 1.4, 1,2 Hz, H-6′), 4.49 (1H, dd, J = 4.7, 3.9 Hz, H-5), 4.69 (1H, ddd, J = 6.2, 3.8, 1.2 Hz, H-3′), 4.74 (1H, d, J = 3.8 Hz, 5′-OH), 4.84 (1H, dd, J = 7.0, 3.9 Hz, H-4), 4.88 (1H, ddd, J = 7.0, 2.9, 0.6 Hz, H-3), 5.15 (1H, d, J = 4.4 Hz, H-6), 6.54 (1H, dd, J = 3.8, 1.4 Hz, H-2′), 6.95 (1H, d, J = 2.9 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.4, 24.4, 24.7, 24.7, 25.7, 25.8, 34.9, 36.3, 36.6, 38.8, 51.6, 52.2, 52.4, 71.0, 71.6, 72.6, 73.7, 76.3, 78.9, 79.5, 111.4, 111.6, 131.5, 133.2, 134.8, 138.8, 165.8, 167.2; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2073.

4.10. Dess-Martin Oxidation of (−)- Followed by NaBH4 Reduction

To a solution of alcohol (−)-8 (0.22 g, 0.38 mmol) in CH2Cl2 (8 mL), DMP (0.20 g, 0.46 mmol) was added at 0 °C, with stirring. The reaction mixture was warmed to RT and stirred for 4 h. The reaction mixture was treated with aqueous Na2S2O3 (20 mL) and sat. aq. NaHCO3 (10 mL), then extracted with TBME (3 × 20 mL). The combined organic layers were washed with brine (30 mL) and water (30 mL), dried over MgSO4, filtered, and concentrated under vacuum to afford an inseparable mixture (0.20 g) of enone 19 and undefined compound 19u, whose carbon skeleton is same as 19 suggested by 2D-NMR analysis of the mixture. Crude 19 and 19u: Oil; HRMS m/z calcd. for C28H35O1035Cl (M)+ of 19, 566.1919; found, 566.1923; 1H-NMR (CDCl3, 600 MHz, ppm) δ 19: 1.20–2.00 (20H, m), 3.77 (3H, s, COOMe), 3.85 (3H, s, COOMe), 4.30 (1H, dd, J = 6.2, 3.2 Hz, H-5), 4.58 (1H, dd, J = 6.5, 0.9 Hz, H-4′), 4.70 (1H, ddd, J = 5.9, 3.0, 1.2 Hz, H-3), 4.77 (1H, dd, J = 5.9, 3.2 Hz, H-4), 4.96 (1H, ddd, J = 6.5, 4.1, 0.9 Hz, H-3′), 5.05 (1H, br d, J = 6.2 Hz, H-6), 5.12 (1H, m, H-6′), 6.75 (1H, br d, J = 3.0 Hz, H-2), 6.83 (1H, dd, J = 4.1, 1.8 Hz, H-2′); 19a: 1.20–2.00 (20H, m), 3.79 (3H, s, COOMe), 3.83 (3H, s, COOMe), 4.15 (1H, ddd, J = 5.9, 1.5, 0.9 Hz, H-4′), 4.21 (1H, br s, H-6′), 4.45 (1H, t, J = 4.4 Hz, H-5), 4.69 (1H, ddd, J = 5.9, 3.5, 0.6 Hz, H-3′), 4.78 (1H, dd, J = 7.6, 2.7 Hz, H-3), 4.90 (1H, dd, J = 7.6, 4.4 Hz, H-4), 5.14 (1H, d, J = 4.4 Hz, H-6), 6.78 (1H, dd, J = 3.5, 0.9 Hz, H-2′), 7.03 (1H, d, J = 2.7 Hz, H-2); 13C-NMR (CDCl3, 150 MHz, ppm) δ 23.52 (CH2), 23.54 (CH2), 23.66 (CH2), 23.75 (CH2), 23.78 (CH2), 23.83 (CH2), 23.88 (CH2), 23.92 (CH2), 24.86 (CH2), 24.91 (CH2), 25.0 (CH2), 25.1 (CH2), 29.7 (CH2), 34.7 (CH2), 35.4 (CH2), 35.6 (CH2), 36.0 (CH2), 36.5 (CH2), 37.0 (CH2), 37.3 (CH2), 49.2 (CH, 19u), 52.22 (CH3), 52.26 (CH3), 52.34 (CH3), 52.4 (CH3), 53.1 (CH, 19), 70.4 (CH, 19u), 71.3 (CH, 19), 71.8 (CH, 19), 72.6 (CH, 19u), 73.2 (CH, 19), 74.8 (CH, 19), 76.2 (CH, 19), 77.2 (CH, 19), 77.7 (CH, 19a), 78.8 (CH, 19), 79.1 (CH, 19u), 79.8 (CH, 19u), 93.7 (Cq, 19), 111.3 (Cq), 111.4 (Cq), 112.3 (Cq), 113.7 (Cq), 129.1 (Cq, 19u), 129.7 (Cq, 19u), 130.8 (Cq, 19), 133.6 (CH, 19), 134.0 (Cq, 19), 136.9 (CH, 19), 137.7 (CH, 19u), 139.6 (CH, 19u), 164.9 (Cq, 19u), 165.2 (Cq, 19), 165.5 (Cq, 19), 166.9 (Cq, 19u), 201.2 (Cq, 19).

To a solution of NaBH4 (13.2 mg, 0.35 mmol) in MeOH (2.5 mL), a solution of crude 19 and 19u (202 mg) in MeOH (10 mL) was added dropwise at 0 °C. After stirring for 30 min, the reaction mixture was treated with sat. aq. NH4Cl (30 mL) and extracted with CH2Cl2 (3 × 30 mL). The organic layer was washed with brine (30 mL), dried over MgSO4, filtered, and concentrated under vacuum to afford a crude residue. Purification by silica gel column chromatography (Hexane–EtOAc, 3:1) afforded (−)-20 (74.0 mg, 34% from 7) as a white amorphous solid. (−)-20: White amorphous solid; [α] −67.5 (c 0.30, CHCl3); IR (liquid film) νmax 3421 (OH), 1719 (C=O), 1656 (C=C) cm−1; 1H-NMR (CDCl3, 600 MHz, ppm) δ 1.20–2.00 (20H, m), 3.71 (1H, m, H-5′), 3.77 (3H, s, COOMe), 3.86 (3H, s, COOMe), 4.34 (1H, dd, J = 5.0, 4.7 Hz, H-5), 4.43–4.45 (1H, m, H-4′), 4.55 (1H, br d, J = 6.5 Hz, H-6′), 4.60 (1H, ddd, J = 5.6, 3.5, 0.6 Hz, H-3′), 4.77 (1H, dd, J = 7.6, 2.7 Hz, H-3), 4.88 (1H, dd, J = 7.6, 4.7 Hz, H-4), 5.05 (1H, br s, OH), 5.07 (1H, d, J = 5.0 Hz, H-6), 6.78 (1H, dd, J = 3.2, 0.9 Hz, H-2′), 6.69 (1H, d, J = 2.7 Hz, H-2); 13C-NMR (CDCl3, 150 MHz, ppm) δ 23.50, 23.55, 23.76, 23.83, 24.9, 25.1, 33.1, 35.0, 36.0, 37.5, 50.5, 52.2, 52.4, 68.6, 70.6, 72.1, 72.3, 74.8, 74.9, 78.9, 111.1, 112.0, 129.2, 129.8, 138.6, 139.5, 165.1, 166.7; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2076.

4.11. Synthesis of (−)-Pericosine E ()

To a solution of alcohol (−)-20 (13.3 mg, 0.023 mmol) in MeOH (0.2 mL), TFA (1.8 mL) was added dropwise dropwise at 0 °C. After stirring for 5 h at RT, the reaction mixture was concentrated under vacuum to afford white crystals. The product was purified by preparative TLC (MeOH-CH2Cl2, 1:9) to afford (−)-6 (9.0 mg, 94%). (−)-6: white crystal; [α] −68.3 (c 0.06, EtOH); IR (liquid film) νmax 3431 (OH), 1729 (C=O), 1657 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.76 (1H, dd, J = 4.1, 2.1 Hz, H-5′), 3.790 (3H, s, COOMe), 3.793 (3H, s, COOMe), 4.06 (1H, br s, H-4′), 4.18 (1H, br d, J = 11.1 Hz, OH), 4.20–4.22 (1H, m, H-4′), 4.21 (1H, br s, H-3), 4.23–4.25 (1H, m, H-3′), 4.34–4.36 (1H, m, H-5), 4.53 (1H, d, J = 4.1 Hz, H-6′), 5.23 (1H, d, J = 2.9 Hz, H-6), 5.33 (1H, br s, OH), 5.61 (1H, br dd, J = 8.8, 0.5 Hz, OH), 6.74 (1H, dd, J = 2.4, 1.4 Hz, H-2′), 7.01 (1H, d, J = 4.4 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 52.45 (CH3), 52.49 (CH3), 53.1 (CH2), 65.5 (CH2), 66.8 (CH2), 69.3 (CH2), 70.5 (CH2), 72.4 (CH2), 77.1 (CH2), 85.6 (CH2), 129.3 (C), 130.4 (C), 143.2 (CH2), 143.5 (CH2), 166.1 (Cq), 166.9 (Cq); HRFABMS m/z calcd. for C16H22O1035Cl (M + H)+, 409.0901; found, 409.0908.

Spectroscopic data of natural 6 [17]: Oil; [α]D −31.5 (c 0.43, EtOH) (racemate as plate from MeOH; mp 213–215 °C; [α]D 0); IR (liquid film) νmax 3326 (OH), 1721 (C=O), 1636 (C=C) cm−1; 1H-NMR (acetone-d6, 500 MHz, ppm) δ 3.76 (1H, br s, H-5′), 3.79 (3H, s, COOMe), 3.79 (3H, s, COOMe), 4.07 (1H, br s, H-4′), 4.22 (1H, m, H-2), 4.23 (1H, br s, 4′-OH), 4.25 (1H, br s, H-3), 4.26 (1H, br s, H-3′), 4.36 (1H, m, H-5), 4.53 (1H, d, J = 4.1 Hz, H-6′), 5.24 (1H, d, J = 3.0 Hz, H-6), 5.37 (1H, br s, 4-OH), 5.64 (1H, br s, 5′-OH), 6.74 (1H, t, J = 1.8 Hz, H-2′), 7.01 (1H, d, J = 3.9 Hz, H-2); 13C-NMR (acetone-d6, 125 MHz, ppm) δ 52.44 (CH3-8), 52.48 (CH3-8′), 53.06 (CH2-6), 65.57 (CH2-3), 66.75 (CH2-4), 69.22 (CH2-3′), 70.43 (CH2-5′), 72.42 (CH2-4′), 77.07 (CH2-6′), 85.52 (CH2-6), 129.23 (Cq-1), 129.91 (Cq-1′), 143.17 (CH2-2), 143.50 (CH2-2′), 166.09 (CH3-8), 166.87 (CH3-8′); HRMS m/z calcd. for C16H22O1035Cl (M + H)+, 409.0900; found, 409.0904.

4.12. Synthesis of (−)-

To a solution of alcohol (−)-8 (21.6 mg, 0.038 mmol) in MeOH (0.2 mL), TFA (1.8 mL) was added dropwise at 0 °C. After stirring for 3 days at RT, the reaction mixture was concentrated under vacuum to afford white crystals. The product was purified by preparative TLC (MeOH-CH2Cl2, 1:9) to give (–)-21 (8.6 mg, 55%). (−)-21: white crystal; [α] −47.1 (c 0.09, EtOH); IR (liquid film) νmax 3344 (OH), 1723 (C=O), 1657 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.72 (3H, s, COOMe), 3.80 (3H, s, COOMe), 4.00 (1H, br dddd, J = 5.3, 4.1, 1.2, 0.8 Hz, H-4′), 4.11 (1H, dd, J = 5.3, 2.4 Hz, H-4), 4.15 (1H, br t, J = 5.0 Hz, H-3), 4.24 (1H, br dd, J = 2.7, 2.6 Hz, H-5), 4.25 (1H, br d, 3.2 Hz, H-6′), 64.46 (1H, ddd, J = 4.1, 2.7, 0.9 Hz, H-3′), 4.50 (1H, dd, J = 5.3, 3.3 Hz, H-5′), 5.23 (1H, d, J = 3.0 Hz, H-6), 6.79 (1H, ddd, J = 2.7, 1.2, 0.6 Hz, H-2′), 7.01 (1H, d, J = 4.7 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 52.24 (CH3), 52.52 (CH3), 52.95 (CH2), 65.67 (CH2), 65.76 (CH2), 66.6 (CH2), 69.06 (CH2), 70.11 (CH2), 76.69 (CH2), 83.54 (CH2), 129.47 (C), 129.54 (C), 142.5 (CH2), 142.7 (CH2), 166.0 (Cq), 166.9 (Cq); HRMS m/z calcd. for C16H21O1035Cl (M)+, 408.0823; found, 408.0821.

4.13. Synthesis of (+)-

To a solution of (+)-10 (0.22 g, 0.83 mmol) and (+)-9 (0.26 g, 0.86 mmol) in CH2Cl2 (3.0 mL), BF3·Et2O (3 μL, 0.011 mmol) was added at 0 °C, then the reaction mixture was stirred at RT. After 10 min, Et3N (20 μL, 0.175 mmol) was added and the mixture was stirred for another 3 h. Solvent removal under reduced pressure gave a crude residue, which was purified by silica gel column chromatography (Hexane–EtOAc, 3:1) to afford (+)-24 as an amorphous solid (0.15 g, 32%). (+)-24: Rf 0.14 (Hexane–EtOAc, 3:1); [α] +131.1 (c 0.135, CHCl3); IR (liquid film) νmax 3471 (OH), 1724 (C=O), 1659 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.26–1.70 (20H, m), 3.78 (3H, s, COOMe), 3.80 (3H, s, COOMe), 4.03 (1H, dd, J = 9.6, 4.7 Hz, H-5′), 4.23 (1H, dd, J = 5.9, 5.6 Hz, H-4′), 4.32 (1H, dd, J = 4.7, 3.8 Hz, H-5), 4.35 (1H, d, J = 4.1 Hz, H-6′), 4.57 (1H, d, J = 4.4 Hz, OH), 4.67 (1H, ddd, J = 6.1, 3.8, 0.9 Hz, H-3′), 4.69 (1H, dd, J = 6.7, 3.8 Hz, H-4), 4.78 (1H, dd, J = 6.5, 3.0 Hz, H-3), 5.16 (1H, d, J = 4.7 Hz, H-6), 6.63 (1H, d, J = 3.9 Hz, H-2′), 6.93 (1H, d, J = 2.9 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.6 (2C), 24.8 (2C), 25.8, 25.9, 35.6, 36.0, 37.0, 38.4, 52.2, 52.4, 52.7, 70.7, 71.1, 71.2, 72.6, 76.2, 77.3, 79.5, 111.2, 111.3, 131.4, 133.2, 135.0, 138.9, 165.9, 167.3; HRMS m/z calcd. for C28H37O10 35Cl (M)+, 568.2075; found, 568.2074.

4.14. Synthesis of (+)-

To a solution of (+)-24 (170 mg, 0.30 mmol) in CH2Cl2 (5 mL), DMP (190 mg, 0.39 mmol) was added at 0 °C, and the mixture was stirred for 4 h at RT. The reaction was quenched by the addition of sat. aq. Na2S2SO4 and sat. aq. NaHCO3 (10 mL) and extracted with TBME (3 × 20 mL). The combined organic layers were washed with brine (30 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure to give a crude residue (180 mg). Without purification, the residue was taken up in methanol (5 mL) and the methanol solution (1 mL) of NaBH4 (11 mg, 0.29 mmol) was added in four portions at 0 °C. After 30 min, the reaction mixture was quenched by the addition of sat aq. NH4Cl (30 mL), extracted with CH2Cl2 (3 × 30 mL). The organic layer was washed with brine, dried over MgSO4, filtered, and the solvent was removed under reduced pressure to give a crude residue, which was purified by silica gel column chromatography (Hexane–EtOAc, 3:1) to afford (+)-25 (100 mg, 59% in two steps) as an oil. (+)-25: R 0.14 (Hexane–EtOAc, 3:1); [α] +60.2 (c 0.665, CHCl3); IR (liquid film) νmax 3460 (OH), 1722 (C=O), 1653 (C=C) cm−1; 1H-NMR (acetone-d, 400 MHz, ppm) δ 1.20–1.70 (20H, m), 3.79 (3H, s, COOMe), 3.81 (3H, s, COOMe), 3.78–3.81 (1H, m, H-5′), 4.37 (1H, dd, J = 5.3, 3.9 Hz, H-4′), 4.48 (1H, br dd, J = 6.4, 3.5 Hz, H-4), 4.58 (1H, d, J = 4.9 Hz, H-6′), 4.75 (1H, d, J = 3.7 Hz, H-3′), 4.76 (1H, d, J = 3.6 Hz, H-5), 4.81 (1H, ddd, J = 6.8, 2.6, 0.8 Hz, H-3), 5.21 (1H, d, J = 5.3 Hz, H-6), 6.76 (1H, dd, J = 3.9, 0.8 Hz, H-2′), 6.88 (1H, d, J = 2.7 Hz, H-2); 13C-NMR (acetone-d, 100 MHz, ppm) δ 24.5, 24.6, 24.6, 24.8, 25.8, 25.8, 35.1, 35.6, 36.7, 37.7, 52.3, 52.6, 53.3, 69.0, 71.4, 72.7, 72.7, 74.6, 75.1, 79.7, 111.1, 111.8, 131.1, 131.1, 138.2, 140.0, 166.4, 166.8; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2077.

4.15. Microwave-Aided Deprotection toward (+)-

To a methanol solution (0.2 mL) of 25 (23.7 mg, 0.042 mmol) in a microwave vial, TFA (1.8 mL) was added at 0 °C. The vial was sealed and irradiated in the MW reactor at 100 °C for 30 min. After cooling, the reaction mixture was condensed under reduced pressure to give a crude residue, which was purified by silica gel column chromatography (MeOH–CH2Cl2, 1:9) to afford (+)-22 (8.0 mg, 47%) as an oil. (+)-22: R 0.3 (MeOH-CH2Cl2, 1:9); [α] +5.7 (c 0.12, EtOH); IR (liquid film) νmax 3404 (OH), 1713 (C=O), 1651 (C=C) cm−1; 1H-NMR (acetone-d6, 400 MHz, ppm) δ 3.64-3.82 (2H, m, OH, H-5), 3.78 (3H, s, COOMe), 3.80 (3H, s, COOMe), 3.84-3.98 (2H, m, OH), 3.92 (1H, br d, J = 7.3 Hz, OH), 3.99 (1H, s, H-4′), 4.02–4.10 (2H, m, H-4, OH), 4.10–4.24 (2H, m, H-3, OH), 4.27 (1H, br s, H-3′), 4.48 (1H, dd, J = 3.1, 2.3 Hz, H-5), 4.57 (1H, d, J = 4.3 Hz, H-6′), 5.38 (1H, d, J = 3.3 Hz, H-6), 6.80 (1H, br d, J = 1.0 Hz, H-2′), 7.04 (1H, d, J = 4.7 Hz, H-2); 13C-NMR (acetone-d6, 100 MHz, ppm) δ 51.49 51.52, 52.9, 64.9, 65.3, 68.2, 68.4, 71.2, 73.1, 82.2, 129.0, 129.1, 141.6, 142.5, 165.0, 166.4; HRMS m/z calcd. for C16H22O1035Cl (M + H)+, 409.0901; found, 409.0896.

4.16. Microwave Aided Deprotection toward (+)-

Using the same procedure as for (+)-22, (+)-24 (22.6 mg, 0.040 mmol) was converted to (+)-23 (10.0 mg, 62%). (+)-23: white crystals; R 0.11 (MeOH-CH2Cl2, 1:9); [α] +75.4 (c 0.340, EtOH); IR (liquid film) νmax 3392 (OH), 1714 (C=O), 1652 (C=C) cm−1; 1H-NMR (acetone-d6, 300 MHz, ppm) δ 3.75 (1H, br s, H-4′), 3.79 (6H, s, COOMe ×2), 4.02 (1H, br s, H-5′), 4.10 (1H, br s, H-4), 4.20 (1H, br s, H-3), 4.37 (2H, br m, H-3′, H-6′), 4.43 (1H, br s, H-5), 5.24 (1H, br d, J = 3.2 Hz, H-6), 6.80 (1H, br s, H-2′), 6.99 (1H, br d, J = 2.9 Hz, H-2); 13C-NMR (acetone-d6, 75 MHz, ppm) δ 52.5, 52.5, 54.5, 66.3, 66.4, 66.6, 70.5, 71.9, 77.1, 83.7, 129.7, 130.7, 141.3, 142.8, 166.1, 167.7; HRMS m/z calcd. for C16H21O1035Cl (M)+, 408.0823; found, 408.0819.

4.17. Synthesis of (+)-

Using the procedure described for (−)-8, (+)-8 (0.092 g, 39%) was prepared from (+)-9 (0.15 g, 0.5 mmol) and (−)-10 (0.11 g, 0.4 mmol). (+)-8: White amorphous solid; [α] +72.7 (c 0.42, CHCl3); IR (liquid film) νmax 3431 (OH), 1729 (C=O), 1653 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.28–1.80 (20H, m), 3.68 (3H, s, COOMe-8′), 3.81 (3H, s, COOMe-8), 4.03 (1H, ddd, J = 7.7, 6.2, 3.5 Hz, H-5′), 4.21 (1H, dd, J = 7.7, 6.2 Hz, H-4′), 4.37 (1H, ddd, J = 6.2, 1.5, 1,2 Hz, H-6′), 4.49 (1H, dd, J = 4.4, 4.1 Hz, H-5), 4.68(1H, ddd, J = 6.1, 4.1, 1.2 Hz, H-3′), 4.73(1H, d, J = 3.5 Hz, OH), 4.84 (1H, dd, J = 7.0, 3.9 Hz, H-4), 4.89 (1H, ddd, J = 7.0, 3.0, 0.6 Hz, H-3), 5.15 (1H, d, J = 4.7 Hz, H-6), 6.54 (1H, dd, J = 4.1, 1.4 Hz, H-2′), 6.95 (1H, d, J = 2.9 Hz, H-2): 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.4, 24.4, 24.7, 24.7, 25.7, 25.8, 34.9, 36.3, 36.6, 38.8, 51.6, 52.2, 52.4, 71.0, 71.6, 72.6, 73.7, 76.3, 78.9, 79.5, 111.4, 111.6, 131.5, 133.2, 134.8, 138.8, 165.8, 167.2; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2074.

4.18. Synthesis of (+)-

Using the same procedure described for (−)-20, (+)-20 (17.0 mg, 22%) was prepared from (+)-8 (78.8 mg, 0.14 mmol). (+)-20: White amorphous solid; [α] +62.1 (c 0.355, CHCl3); IR (liquid film) νmax 3423 (OH), 1722 (C=O), 1656 (C=C) cm−1; 1H-NMR (CDCl3, 300 MHz, ppm) δ 1.20–2.00 (20H, m), 3.70–3.80 (1H, m, H-5′), 3.77 (3H, s, COOMe), 3.86 (3H, s, COOMe), 4.34 (1H, t, J = 4.6 Hz, H-5), 4.42–4.46 (1H, m, H-4′), 4.55 (1H, br d, J = 6.9 Hz, H-6′), 4.61 (1H, dd, J = 5.5, 3.3 Hz, H-3′), 4.77 (1H, dd, J = 7.5, 2.3 Hz, H-3), 4.88 (1H, dd, J = 7.5, 4.3 Hz, H-4), 5.06 (1H, br s, OH), 5.07 (1H, d, J = 4.8 Hz, H-6), 6.78 (1H, dd, J = 3.4, 0.9 Hz, H-2′), 6.98 (1H, d, J = 2.3 Hz, H-2); 13C-NMR (CDCl3, 75 MHz, ppm) δ 23.5, 23.5, 23.8, 23.8, 24.9, 25.0, 33.1, 35.0, 36.0, 37.5, 50.5, 52.2, 52.5, 68.6, 70.6, 72.1, 72.3, 74.8, 74.8, 78.9, 111.1, 112.0, 129.2, 129.8, 138.6, 139.5, 165.1, 166.8; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2079.

4.19. Synthesis of (+)-

Using the same procedure described for (−)-6, (+)-6 (11.3 mg, 90%) was prepared from (+)-20 (17.4 mg, 0.031 mmol). (+)-6: white crystal; [α] +73.3 (c 0.085, EtOH); IR (KBr) νmax 3435 (OH), 1713 (C=O), 1643 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.74–3.78 (1H, m, H-5′), 3.788 (3H, s, COOMe), 3.789 (3H, s, COOMe), 4.07 (1H, br s, H-4′), 4.20–4.30 (4H, m, OH, H-4′, H-3, H-3′), 4.36 (1H, br dd, J = 1.4, 1.2 Hz, H-5), 4.53 (1H, d, J = 4.1 Hz, H-6′), 5.24 (1H, d, J = 2.9 Hz, H-6), 5.40 (1H, br s, OH), 5.66 (1H, br d, J = 7.0 Hz, OH), 6.74 (1H, s, H-2′), 7.01 (1H, d, J = 4.2 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 52.46 (CH3), 52.50 (CH3), 53.1 (CH2), 65.6 (CH2), 66.7 (CH2), 69.2 (CH2), 70.4 (CH2), 72.4 (CH2), 77.1 (CH2), 85.5 (CH2), 129.2 (C), 129.9 (C), 143.2 (CH2), 143.5 (CH2), 166.1 (Cq), 166.9 (Cq); HRMS m/z calcd. for C16H22O1035Cl (M)+, 408.0823; found, 408.0819.

4.20. Synthesis of (+)-

Using the same procedure described for (−)-21, (+)-21 (0. 9 mg, 63%) was prepared from (+)-8 (20.0 mg, 0.035 mmol). (+)-21: oil; [α] −40.5 (c 0.035, EtOH); IR (liquid film) νmax 3389 (OH), 1721 (C=O), 1653 (C=C) cm−1; 1H-NMR (acetone-d6, 300 MHz, ppm) δ 3.72 (3H, s, COOMe), 3.80 (3H, s, COOMe), 4.00 (1H, br s, H-4′), 4.09–4.20 (2H, m, H-3, H-4), 4.20–4.30 (1H, m, H-5, H-6′), 4.46 (1H, br s, H-3′), 4.50 (1H, br s, H-5′), 5.23 (1H, d, J = 2.6 Hz, H-6), 6.79 (1H, s, H-2′), 7.01 (1H, br d, J = 3.5 Hz, H-2); 13C-NMR (acetone-d6, 75 MHz, ppm) δ 52.3 (CH3), 52.5 (CH3), 52.9 (CH2), 65.7 (CH2), 65.8 (CH2), 66.7 (CH2), 69.1 (CH2), 70.1 (CH2), 76.7 (CH2), 83.5 (CH2), 129.5 (C), 129.5 (C), 142.5 (CH2), 142.7 (CH2), 166.0 (Cq), 166.9 (Cq); HRMS m/z calcd. for C16H21O1035Cl (M)+, 408.0823; found, 408.0819.

4.21. Synthesis of (−)-

Using the same procedure described for (+)-24, (−)-24 (0.25 g, 35%) was prepared from (−)-9 (0.45 g, 1.5 mmol) and (−)-10 (0.33 g, 1.2 mmol). (−)-24: amorphous solid; R 0.14 (Hexane–EtOAc, 3:1); [α] −126.47 (c 0.825, CHCl3); IR (liquid film) νmax 3470 (OH), 1722 (C=O), 1658 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 1.26–1.70 (20H, m), 3.78 (3H, s, COOMe), 3.80 (3H, s, COOMe), 4.03 (1H, br ddd, J = 5.0, 4.7, 4.4 Hz, H-5′), 4.22 (1H, dd, J = 6.1, 5.3 Hz, H-4′), 4.32 (1H, dd, J = 4.7, 3.8 Hz, H-5), 4.35 (1H, dd, J = 4.4, 0.9 Hz, H-6′), 4.55 (1H, d, J = 4.7 Hz, OH), 4.67 (1H, ddd, J = 6.1, 3.8, 1.1 Hz, H-3′), 4.69 (1H, dd, J = 6.4, 3.8 Hz, H-4), 4.78 (1H, ddd, J = 6.7, 3.0, 0.6 Hz, H-3), 5.16 (1H, d, J = 4.7 Hz, H-6), 6.63 (1H, d, J = 3.8 Hz, H-2′), 6.93 (1H, d, J = 2.9 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 24.6 (2C), 24.8 (2C), 25.8, 25.9, 35.6, 36.0, 36.9, 38.4, 52.2, 52.4, 52.7, 70.8, 71.1, 71.2, 72.6, 76.2, 77.3, 79.5, 111.2, 111.3, 131.4, 133.2, 135.0, 138.9, 165.9, 167.3; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2079.

4.22. Synthesis of (−)-

Using the same procedure described for (–)-21, (+)-21 (0.066 g, 39%) was prepared from (−)-24 (0.17 g, 0.30 mmol). (−)-25: oil; R 0.14 (Hexane–EtOAc, 3:1); [α] −43.3 (c 0.085, CH2Cl2); IR (liquid film) νmax 3523 (OH), 1717 (C=O), 1653 (C=C) cm−1; 1H-NMR (acetone-d, 600 MHz, ppm) δ 1.20–1.70 (20H, m), 3.79 (3H, s, COOMe), 3.81 (3H, s, COOMe), 3.78–3.81 (1H, m, H-5′), 4.36 (1H, dd, J = 5.3, 3.9 Hz, H-4′), 4.48 (1H, dd, J = 6.5, 3.5 Hz, H-4), 4.58 (1H, d, J = 5.0 Hz, H-6′), 4.75 (1H, d, J = 3.9 Hz, H-3′), 4.76 (1H, dd, J = 3.8, 0.9 Hz, H-5), 4.81 (1H, ddd, J = 6.7, 2.7, 0.9 Hz, H-3), 5.21 (1H, d, J = 5.3 Hz, H-6), 6.76 (1H, dd, J = 3.8, 0.9 Hz, H-2′), 6.88 (1H, d, J = 2.7 Hz, H-2); 13C-NMR (acetone-d, 150 MHz, ppm) δ 24.5, 24.6, 24.6, 24.9, 25.8, 25.9, 35.1, 35.7, 36.7, 37.7, 52.3, 52.6, 53.3, 69.0, 71.4, 72.7, 72.8, 74.6, 75.2, 79.7, 111.1, 111.8, 131.1, 131.2, 138.2, 140.0, 166.4, 166.8; HRMS m/z calcd. for C28H37O1035Cl (M)+, 568.2075; found, 568.2076.

4.23. Synthesis of (−)-

Using the same procedure described above for (−)-22, (+)-22 (5.9 mg, 33%) was prepared from (−)-25 (25 mg, 0.043 mmol). (−)-22: oil; R 0.3 (MeOH-CH2Cl2, 1:9); [α] −5.0 (c 0.225, EtOH); IR (liquid film) νmax 3391 (OH), 1716 (C=O), 1651 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.68 (1H, br d, J = 10.0 Hz, OH), 3.76–3.82 (1H, m, H-5), 3.78 (3H, s, COOMe), 3.80 (3H, s, COOMe), 3.86 (1H, br d, J = 10.3 Hz, OH), 3.92 (1H, br d, J = 7.3 Hz, OH), 3.99 (1H, s, H-4′), 4.01–4.08 (2H, m, H-4, OH), 4.12–4.18 (2H, m, H-3, OH), 4.26 (1H, s, H-3′), 4.47 (1H, dd, J = 2.9, 2.4 Hz, H-5), 4.57 (1H, d, J = 4.1 Hz, H-6′), 5.38 (1H, d, J = 3.3 Hz, H-6), 6.80 (1H, dd, J = 2.3, 1.2 Hz, H-2′), 7.04 (1H, d, J = 5.0 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 52.40, 52.43, 53.87, 65.89, 66.20, 69.09, 69.33, 72.18, 74.01, 83.18, 129.93, 130.07, 142.56, 143.34, 165.95, 167.33; HRFABMS m/z calcd. for C16H22O1035Cl (M + H)+, 409.0901; found, 409.0900.

4.24. Synthesis of (−)-

Using the same procedure described above for (+)-23, (−)-23 (7.6 mg, 50%) was prepared from (−)-24 (21.3 mg, 0.038 mmol). (−)-23: white crystals; R 0.11 (MeOH-CH2Cl2, 1:9); [α] −75.3 (c 0.095, EtOH); IR (liquid film) νmax 3349 (OH), 1716 (C=O), 1593 (C=C) cm−1; 1H-NMR (acetone-d6, 600 MHz, ppm) δ 3.75 (1H, dd, J = 6.7, 4.1 Hz, H-4′), 3.79 (6H, s, COOMe), 4.02 (1H, d, J = 6.8, 4.1 Hz, H-5′), 4.10 (1H, br s, H-4), 4.21 (1H, br s, H-3), 4.36 (1H, d, J = 4.1 Hz, H-6′), 4.37 (1H, dd, J = 4.1, 3.8 Hz, H-3′), 4.43 (1H, dd, J = 3.6, 2.0 Hz, H-5), 5.24 (1H, d, J = 3.5 Hz, H-6), 6.79 (1H, d, J = 3.5 Hz, H-2′), 6.99 (1H, d, J = 4.4 Hz, H-2); 13C-NMR (acetone-d6, 150 MHz, ppm) δ 52.4, 52.5, 54.5, 66.3, 66.4, 66.6, 70.6, 71.9, 77.2, 83.7, 129.8, 130.8, 141.3, 1412.7, 166.1, 167.1; HRMS m/z calcd. for C16H21O1035Cl (M)+, 408.0823; found, 408.0821.

4.25. Glycosidase Assays of Synthesized Compounds

: The assay reaction mixture consisted of 0.1 M acetate buffer (pH 5.0, 45 μL), p-nitrophenyl α-d-glucopyranoside solution (25 μL, 250 mM), and α-glucosidase solution (25 μL, a stock solution of 1.0 mg/mL in 50 mM Tris-HCl-buffer at pH 7.8 diluted 200-fold with 10 mM phosphate buffer at pH 7.0 just prior to the assay), with the test samples 6, 21–23, or DNJ (25 μL solution, concentration range 0.1–20 mg/mL). After incubation for 20 min at 37 °C, the reaction was interrupted by the addition of 0.5 M sodium carbonate (100 μL). The amount of p-nitrophenol liberated was measured colorimetrically at 400 nm (optical density at 400 nm: ODtest). The inhibition rates (%) were calculated using the formula 100 − 100 × (ODtest − ODblank)/(control ODtest − control ODblank) and the IC50 values were obtained from the inhibition curves. Assays for β-glucosidase and α-mannosidase were carried out as outlined above using p-nitrophenyl β-d-glucopyranoside and α-d-mannopyranoside as the substrates. The IC50 values are shown in Table 1.

Assays on β-glucosidase and α-mannnosidase inhibition of synthesized carbadisaccharides 6 and 21–23 were carried out in a similar fashion.